US › Healthcare

Legend Biotech Corp (LEGN)

US · Healthcare · Biotechnology

$17.58+3.41%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$387.5M

Revenue YoY

+51.9%

Net profit

$33.2M

EPS

$0.09

EPS estimate

$0.12

Net margin

8.6%

EPS came in at 0.09 against a street estimate of 0.12 — a miss of 25.0%.

Key statistics

Market cap

$3.63B

Forward P/E

27.8

P/B

2.95

Book value

$6.35

EPS (TTM)

$-0.50

52-week high

$37.50

52-week low

$16.24

50-day MA

$21.92

200-day MA

$22.96

Beta

0.40

Analyst view

Analysts rate Legend Biotech Corp a buy (21 buy, 1 hold, 0 sell out of 22) with an average price target of $48.48.

Shareholding

Insiders

1.25%

Institutions

56.74%

Largest institutional holders

Fund	Stake
FMR Inc	13.21%
Deerfield Management Co	3.95%
Suvretta Capital Management, LLC	3.90%
Hillhouse Capital Advisors, Ltd.	3.08%
BlackRock Inc	2.41%
Westfield Capital Management Company, L.P.	2.28%
Point72 Asset Management, L.P.	2.00%
Kynam Capital Management, LP	1.54%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Legend Biotech Corp — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.